Featuring a slide presentation and related discussion from Dr Justin Gainor, including the following topics:
- Biology of RET Genetic Alterations in Cancer (0:00)
- Early Efforts to Target RET Alterations in Non-Small Cell Lung Cancer (NSCLC) (1:44)
- Mechanisms of Action of Selective RET Inhibitors (3:58)
- Clinical Trial Evidence Supporting Selpercatinib Therapy for RET-Altered NSCLC (5:04)
- Updated Efficacy and Safety Results with Pralsetinib Therapy for RET-Altered NSCLC (13:14)
- Mechanisms of Resistance to Selective RET Inhibitors (19:33)
CME information and select publications